164463-15-4

Upstream product

• 104-92-7 1-bromo-4-methoxy-benzene 
• 699-98-9 Pyridine-2,3-dicarboxylic anhydride 
• 13139-86-1 4-methoxyphenyl magnesium bromide 

Downstream Products

• 862816-19-1 5-(4-methoxyphenyl)-7H-pyrido[2,3-d]pyridazin-8-one 
• 211630-10-3 8-(4-methoxyphenyl)-6H-pyrido[2,3-d]pyridazin-5-one 
• 164463-18-7 6-ethoxycarbonyl-5-hydroxy-7-(4-methoxyphenyl)-5-(3,4-methylenedioxyphenyl)-5H-cyclopenta[b]pyridine 

Relevant academic research and scientific papers

6-Carboxy-5,7-diarylcyclopenteno[1,2-b]pyridine derivatives: a novel class of endothelin receptor antagonists.

Compounds (2-5) with a 6-carboxy-5,7-diarylcyclopentenopyridine skeleton were designed, synthesized, and identified as a new class of potent non-peptide endothelin receptor antagonists. The regio-isomer 2 was found to show potent inhibitory activity with an IC(50) value of 2.4 nM against (125)I-labeled ET-1 binding to human ET(A) receptors and a 170-fold selectivity for ET(A) over ET(B) receptors. Furthermore, 2 displayed more potent in vivo activity than did the indan-type compound 1 in a mouse ET-1 induced lethality model, suggesting the potential of 2 as a new lead structure. Derivatization on substituted phenyl groups at the 5- and 7-positions of 2 revealed that a 3,4-methylenedioxyphenyl group at the 5-position and a 4-methoxyphenyl group at the 7-position were optimal for binding affinity. Further derivatization of 2 by incorporating a substituent into the 2-position of the 4-methoxyphenyl group led to the identification of a more potent ET(A) selective antagonist 2p with an IC(50) value of 0.87 nM for ET(A) receptors and a 470-fold selectivity. In addition, 2p showed highly potent in vivo efficacy (AD(50): 0.04 mg/kg) in the lethality model.

ENDOTHELIN ANTAGONISTIC HETEROAROMATIC RING-FUSED CYCLOPENTENE DERIVATIVES

A heteroaromatic ring-fused cyclopentene derivative of the formula: STR1 wherein the variables are as defined in the specification; or a pharmaceutically acceptable salt thereof.

Benzopyridazinone and pyridopyridazinone compounds

Benzo or pyridopyridazinones and pyridazinthiones of the formula STR1 wherein: X and Y are nitrogen or carbon, provided that at least one is carbon, and Z is oxygen or sulfur; R1 is hydrogen, lower alkyl, aryl, aralkyl, heterocyclo, heterocyclo lower-alkyl, heteroaryl, or heteroaralkyl; R2, R3, R4, R5 and R6 are independently selected from hydrogen, lower alkyl, halo, carboxy, alkoxycarbonyl, carbamoyl, lower-alkyl carbonyl, halocarbonyl, thiomethyl, trifluoromethyl, cyano or nitro; or a pharmaceutically acceptable ester, ether or salt thereof, have been found to be useful as an anti-inflammatory, antasthmatic, immunosuppressive, anti-allograft rejection, anti-graft-vs-host rejection, autoimmune disease or analgetic agent(s).

Heterocyclic compounds, their production and use as tachykinin reactor antagonists

A novel compound represented by the formula: STR1 wherein Ring A and Ring B respectively stands for an optionally substituted homo- or hetero-cyclic ring, and at least one of them stands for an optionally substituted heterocyclic ring stand; Ring C stands for an optionally substituted benzene ring; R stands for a hydrogen atom or an optionally substituted hydrocarbon residue; one of X and Y stands for --NR1 -- (R1 stands for a hydrogen atom or an optionally substituted hydrocarbon residue) or --O--, and the other stands for--CO-- or --CS--, or one of them stands for --N= and the other stands for =CR2 -- (R2 stands for a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon residue, an optionally substituted amino group or an optionally substituted hydroxyl group); n denotes 1 or 2 or salts thereof which have an excellent tachykinin receptor antagonistic action and inhibitory action on plasma extravasation.

ENDOTHELIN ANTAGONISTIC HETEROAROMATIC RING-FUSED CYCLOPENTENE DERIVATIVES

A heteroaromatic ring-fused cyclopentene derivative of the formula: STR1 wherein the variables are as defined in the specification; or a pharmaceutically acceptable salt thereof.